Annals of General Psychiatry

, 5:S158 | Cite as

Neurocognitive evaluation of oxcarbazepine monotherapy in children with benign chilhood epilepsy

  • Maria Tzitiridou
  • Dora Panou
  • Athanasios Kambas
  • Christos Panteliadis
Open Access
Poster presentation


Phonological Awareness Oxcarbazepine Magnetic Imaging Epilepsy Syndrome Childhood Epilepsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


To explore the impact of oxcarbazepine (OXC) monotherapy on terms of cognitive functions and academic achievement in patients with benign childhood epilepsy with centro-temporal spikes (BECTS).

Materials and methods

A total of 71 patients aged 5.6 to 11.4 years (45 males, 25 females, mean 8.5 ± 0.7) with typical clinical and EEG features of BECTS were assigned to OXC monotherapy. Inclusion criteria were a) newly diagnosed epilepsy, b) 3 or more seizures during the past 6 months c) normal brain magnetic imaging. All of them underwent psychometric assessment at screening and after 18 months of treatment by means of WISC-III, Illinois Test of Psychomotor Abilities, DSM-IV, and Bender-Santucci Test. Seizure types, frequency, awake and sleep EEG findings, dosage ranges were documented. The Mann-Whitney U test was used to describe differences 1) at initial evaluation, comparing patients with a group of 45 age-matched unaffected controls and 2) after 18 months of OXC monotherapy, as an individual follow-up in the patient group.


Cognitive assessment revealed learning deficits in 7/71 patients and 3/45 controls at baseline. This subgroup marked difficulties in reasoning, computational skill, phonological awareness and short-term visuospatial memory. No child had a persistent stagnation or a regression in cognitive abilities after treatment. The identification of these disabilities was crucial to the parents' information and strategy development. The initial weak scores in isolated domains improved or normalised during the study with concomitant EEG improvement or normalisation and effective seizure control.


Oxcarbazepine is a novel antiepileptic drug with tested efficacy and tolerability. Ours findings suggest that OXC has a favourable cognitive profile and may prove a key medication for improving the outcome of this epilepsy syndrome


  1. 1.
    Binnie CD: Cognitive impairment during epileptiform discharges: is it ever justifiable to treat the EEG?. Lancet Neurology. 2003, 2: 725-730. 10.1016/S1474-4422(03)00584-2.CrossRefPubMedGoogle Scholar
  2. 2.
    Metz-Lutz M, Kleitz C: Cognitive Development in Benign Focal Epilepsies of Childhood. Dev Neurosci. 1999, 21: 182-190. 10.1159/000017397.CrossRefPubMedGoogle Scholar
  3. 3.
    Loring DW: Cognitive side effects of antiepileptic drugs in children. Neurology. 2004, 62: 872-877.CrossRefPubMedGoogle Scholar
  4. 4.
    Tzitiridou : Oxcarbazepine monotherapy in benign chilhood epilepsy with centro-temporal spikes: a clinical and cognitive evaluation. Epilepsy and Behaviour. 2005,Google Scholar

Copyright information

© The Author(s) 2006

Authors and Affiliations

  • Maria Tzitiridou
    • 1
  • Dora Panou
    • 2
  • Athanasios Kambas
    • 2
  • Christos Panteliadis
    • 2
  1. 1.Department of Paediatric Neurology and Developmental Medicine, Children's HospitalUniversity of MunichGermany
  2. 2.3rd Pediatric DepartmentAristotle University, Hippokration HospitalThessalonikiGreece

Personalised recommendations